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Transcription factors with identical DNA-binding specifi-
city often activate different genes in vivo. Yeast Ace2 and
Swi5 are such activators, with targets we classify as Swi5-
only, Ace2-only, or both. We define two unique regulatory
modes. Ace2 and Swi5 both bind in vitro to Swi5-only
genes such as HO, but only Swi5 binds and activates in
vivo. In contrast, Ace2 and Swi5 both bind in vivo to Ace2-
only genes, such as CTS1, but promoter-bound Swi5 fails
to activate. We show that activation by Swi5 is prevented
by the binding of the Forkhead factors Fkh1 and Fkh2,
which recruit the Rpd3(Large) histone deacetylase com-
plex to the CTS1 promoter. Global analysis shows that all
Ace2-only genes are bound by both Ace2 and Swi5, and
also by Fkh1/2. Genes normally activated by either Ace2
or Swi5 can be converted to Ace2-only genes by the
insertion of Fkh-binding sites. Thus Fkh proteins, which
function initially to activate SWI5 and ACE2, subsequently
function as Swi5-specific antiactivators.
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Introduction
Transcription factors with identical DNA-binding domains
can activate different genes in vivo, and this constitutes an
important unsolved puzzle in gene regulation. Proposed
explanatory models include combinatorial control with
other DNA-binding factors or subtle differences in binding
affinity not detected in vitro. Here we present a different
paradigm.
Ace2 and Swi5 are cell-cycle-regulated transcription factors
in Saccharomyces cerevisiae that activate genes expressed in
late M and early G1 phase (Simon et al, 2001). Ace2 and Swi5
have essentially identical DNA-binding domains and recog-
nize the same sequences in vitro (Dohrmann et al, 1996), but
they activate different genes in vivo (Dohrmann et al, 1992).
For instance, the HO gene is only activated by Swi5, while
CTS1 is only activated by Ace2. We show that Fkh1 and Fkh2
can act as selective antiactivators, blocking Swi5, but not
Ace2, from activating transcription. Fkh1 and Fkh2 are G2/M
phase-specific activators for a set of genes that includes Ace2
and Swi5. Fkh1 and Fkh2 also function as repressors at CTS1,
but only against Swi5-dependent activation even though Swi5
and Ace2 bind equivalently to the promoter. This specific
antiactivation requires recruitment of the Rpd3(Large) his-
tone deacetylase (HDAC) complex. Our global analysis sug-
gests that this mechanism operates in vivo at all yeast genes
that are bound by these factors. Moreover, we show that Fkh
antiactivation is transferable. Promoters that are naturally
activated by either Swi5 or Ace2 can be converted to an Ace2-
only activation program by insertion of Fkh-binding sites.
Results and discussion
Genetic identification of CTS1 NRE and Fkh regulatory
factors
We identified a negative regulatory element (NRE) in the
CTS1 promoter which, when deleted or mutated, allowed
Swi5 to activate a CTS1-lacZ plasmid reporter (Dohrmann
et al, 1996). This NRE was localized to 66 bps located
between 404 and 470 bp upstream of the ATG of CTS1,
with two Ace2-binding sites located nearby, between 520
and 545 bp (Figure 1A). The NRE represses activation
independent of position, orientation, and promoter context
(Dohrmann et al, 1996). We precisely deleted the minimal
NRE region from the genomic CTS1 promoter, eliminating
concerns about effects of a plasmid-based assay or the use of
a lacZ reporter gene. This CTS1(nreD) allele was introduced
into strains with mutations in ACE2 and SWI5, and expres-
sion of wild-type CTS1 and CTS1(nreD) were measured
(Figure 1B). The native CTS1 gene is not expressed in the
ace2 mutant (column 3), but strong expression of CTS1(nreD)
is seen even in the absence of the normally required Ace2
activator (column 7). Furthermore, activation of CTS1(nreD)
is Swi5-dependent, since expression is lost in the ace2 swi5
CTS1(nreD) strain (column 8). We also constructed a mutant
CTS1(nre-m) promoter with sequence substitutions through-
out the NRE, maintaining the spacing between the Swi5/
Ace2-binding sites and the transcription start site, and this
mutant promoter showed similar activation by Swi5
(Figure 1B, columns 11–12). Thus, the NRE element in the
CTS1 promoter prevents bound Swi5 from activating CTS1
transcription. We note that the NRE deletion does not fully
restore CTS1 expression in the absence of Ace2, suggesting
that additional repressive mechanisms are still present in the
CTS1(nreD) promoter.
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A genetic screen was carried out to identify mutations in
genes that normally prevent Swi5 from activating CTS1
(Dohrmann et al, 1996). An ace2 strain with an integrated
CTS1-lacZ reporter was mutagenized and suppressors were
identified as blue colonies in the presence of the X-Gal
chromogenic substrate. Genetic analysis and complementa-
tion cloning for one suppressor mutation, nce11, identified
plasmids containing the FKH2 gene. Segregation analysis
demonstrated that the nce11 mutations were allelic with an
fkh2 disruption allele. FKH2 encodes a member of the winged
helix superfamily of DNA-binding transcription factors. Fkh2
and its paralog Fkh1 are redundant activators that bind to the
promoters of the CLB2 group of genes expressed in G2,
including CLB2, SWI5, and ACE2 (Hollenhorst et al, 2000;
Koranda et al, 2000; Kumar et al, 2000; Pic et al, 2000; Zhu
et al, 2000). Strains with single mutations in FKH1 or FKH2
are predominantly normal in cell cycle progression, but fkh1
fkh2 double mutant strains exhibit strong defects consistent
with reduced CLB2 expression. Although we only obtained an
fkh2 mutant in our initial screen, we included FKH1
in subsequent analyses, based on its close homology and
known functional overlap with FKH2.
Fkh1 and Fkh2 bind CTS1 and repress via the NRE
element
Strains were constructed to assess the contributions of FKH1
and FKH2 in blocking Swi5 activation of CTS1. Deletion of
either FKH1 or FKH2 weakly suppresses the ace2 defect in
CTS1 expression, allowing Swi5 to activate CTS1 at 2–3 times
the level observed in an ace2 mutant; similar effects were
seen with both an integrated CTS1-lacZ reporter (Figure 1C)
and the native CTS1 gene (Figure 1D). Suppression of the
ace2 defect in CTS1 expression requires Swi5. Thus, muta-
tions in either fkh1 or fkh2 have similar effects, allowing Swi5
to inappropriately activate expression of CTS1.
Transcription of the SWI5 gene is normally activated by
Fkh1/2 (Hollenhorst et al, 2000; Koranda et al, 2000; Kumar
et al, 2000; Pic et al, 2000; Zhu et al, 2000), so the non-
additive suppression of the ace2 transcriptional defect in the
fkh1 fkh2 double mutant (Figure 1C and D) could be due to
decreased SWI5 expression. To address this problem, a similar
set of strains was constructed with SWI5 expressed from the
MET17 promoter. MET17 expression under noninducing con-
ditions is Fkh-independent and occurs at S/G2 (Spellman
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Figure 1 The NRE in the CTS1 promoter blocks activation by Swi5. (A) Map shows the Ace2/Swi5-binding sites at 546 and 526 from the
ATG codon, the negative regulatory element (NRE) defined by deletion analysis as from 470 to 418 (Dohrmann et al, 1996), and the TATA
element at 313. The transcription start site is at 238 (Dohrmann et al, 1992). The four Fkh-binding sites within the NRE are shown. The
alignment shows the Fkh consensus site (Zhu et al, 2000), the sites from the CTS1 NRE and the ‘TG’ mutation in NRE site 4 (Dohrmann et al,
1996). (B) Swi5 activates CTS1(nreD). RNAs were used for RT-real-time–PCR assays to measure CTS1 RNA levels. RNA values are normalized
to the CTS1(WT) ACE2 SWI5 strain (defined as 100), and the error bars show the standard deviation of the triplicate PCR reactions. (C) Swi5
weakly activates CTS1-lacZ in an fkh1 fkh2 mutant by b-galactosidase activity from CTS1-lacZ. LacZ values are normalized to the ACE2 SWI5
FKH1 FKH2 strain (defined as 100), and the error bars show the standard deviation of triplicate cultures for lacZ assays. (D) Swi5 weakly
activates CTS1 in an fkh1 fkh2 mutant by S1 nuclease protection assay. (E) Swi5 activates CTS1-lacZ in an fkh1 fkh2 mutant when Swi5 is
expressed from the Fkh-independent MET17 promoter. LacZ values are normalized to the ACE2 SWI5 FKH1 FKH2 strain (defined as 100), and
the error bars show the standard deviation of triplicate cultures for lacZ assays. (F) Fkh1 and Fkh2 repress CTS1 via the NRE element by S1
nuclease protection assay.
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this METpHSWI5 construct retains the post-translational
signals for regulated nuclear localization and degradation
within the cell cycle. Immunoblot quantitation shows levels
of Swi5 expressed from the MET17 promoter are less than
two-fold above native Swi5 (data not shown). Using this
METpHSWI5 allele, CTS1 expression in the absence of Ace2
increased four- to five-fold with either a fkh1 or fkh2 single
mutation, and the ace2 fkh1 fkh2 mutant showed CTS1
expression levels about nine-fold over that of ace2 alone
(Figure 1E). The additive increase in Swi5-dependent CTS1
expression in the fkh1 fkh2 double mutant indicates that the
Fkh1 and Fkh2 factors are partially redundant for inhibiting
CTS1 activation by Swi5, but both are required for full
repression. In contrast, we do not see additivity in the fkh1
fkh2 double mutant when SWI5 is expressed from its native
Fkh1/2-dependent promoter (Figure 1C and D). The additive
effect in the fkh1 fkh2 double mutant when SWI5 is expressed
from the Fkh-independent MET17 promoter (Figure 1E) in-
dicates that the Fkh proteins are redundant. Additionally,
combining the fkh1 and fkh2 mutations with the NRE dele-
tion shows only a minor increase in suppression relative to
the effect of the NRE deletion alone (Figure 1F). This com-
parative lack of additivity is consistent with Fkh1/2 acting
through the NRE element at CTS1.
The CTS1 NRE region contains four matches to the con-
sensus Fkh1-binding site (Zhu et al, 2000), with one site
being a perfect match (Figure 1A). We previously identified a
two-nucleotide substitution in the NRE region that allows
Swi5 activation (Dohrmann et al, 1996), and these changes
are within the perfect Fkh consensus site. Chromatin immuno-
precipitation (ChIP) shows that Fkh1 and Fkh2 both bind to
the CTS1 and CLB2 promoters, but no binding was seen to the
CTS1(nreD) allele (Figure 2A and B) demonstrating that Fkh1
and Fkh2 bind specifically to the NRE region of the CTS1
promoter.
Binding of the Rpd3(Large) complex to the NRE element
Recent work has suggested that Fkh2 recruits the Isw2
remodeling factor to promoters, and that Isw2 contributes
to transcriptional repression (Sherriff et al, 2007). To inves-
tigate whether Isw2, or its paralog Isw1, were involved in
blocking Swi5 activation at CTS1, we constructed ace2 isw2,
ace2 isw1, and ace2 isw1 isw2 strains. The substantial reduc-
tion in CTS1 mRNA levels caused by an ace2 mutation is not
suppressed by isw1 or isw2 mutations (data not shown), and
we conclude that these chromatin regulators do not repress at
CTS1. We next examined sin3 and rpd3 mutations, as Sin3
was identified as interacting with Fkh1 and Fkh2 in a global
protein interaction screen (Ho et al, 2002), and Rpd3 is

























Figure 2 Fkh1 and Fkh2 bind to the CTS1 NRE. (A) ChIP assay
shows Fkh1-HA binding to CTS1 and CLB2. Deletion of the NRE
eliminates Fkh1 binding. Error bars show the standard deviation of
the ChIP PCR reactions performed in triplicate. (B) ChIP assay
shows Fkh2-Myc binding to CTS1 and CLB2. Deletion of the NRE
eliminates Fkh2 binding. Error bars show the standard deviation of
the ChIP PCR reactions performed in triplicate. (C) ChIP assays from
synchronized Ace2-Myc GAL-CDC20 cells show Ace2 binding to
CTS1 but not HO. Flow cytometry profiles show the quality of the
cell cycle synchrony. The vast majority of these haploid cells have
an apparent 2C DNA content even at later time points, as cells
release and progress into G1 without cell separation, which is only
beginning at the 45 min time point. The strain has an swi5 mutation,
and the modest defect in cell separation in an swi5 mutant
(Dohrmann et al, 1992) results also in a small number of cells
with apparent 4C DNA content. Progression from mitotic arrest
through G1 and into S phase was also confirmed by synchronous
bud formation at later time points (data not shown). (D) ChIP
assays from synchronized Swi5-Myc GAL-CDC20 cells show Swi5
binding to HO and CTS1. (E) ChIP assay shows Fkh1-HA from log
phase cells binding to the CLB2 promoter but not the CLB2 ORF.
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that repress transcription (Kurdistani and Grunstein, 2003).
CTS1 mRNA levels are higher in ace2 sin3 and ace2 rpd3
strains than in an ace2 single mutant, indicating that Sin3/
Rpd3 is involved in CTS1 repression (Figure 3A and B).
At least two HDAC complexes contain Rpd3 (Carrozza
et al, 2005; Keogh et al, 2005). The Rpd3(Large) complex
is present primarily at promoters while Rpd3(Small) acts
primarily at transcribed open reading frames (ORFs). While
both complexes contain Sin3 and Rpd3, there are unique
subunits such as Sds3 present only in Rpd3(Large), and Rco1
present only in Rpd3(Small). An sds3 mutation allows CTS1
expression in the absence of Ace2, while an rco1 mutation
does not (Figure 3A and C), and thus Rpd3(Large) represses
CTS1. The CTS1(nreD) allele also allows CTS1 activation by
Swi5, but there is no additive effect from combining this
promoter mutation with either sin3 or sds3 in the ace2 SWI5
strains. This lack of additivity suggests that Rpd3(Large)
represses CTS1 expression via the NRE element. As seen for
the NRE deletion, neither sin3 nor sds3 mutations fully
restore CTS1 expression in the absence of Ace2, suggesting
additional mechanisms of repression. Finally, while sin3 and
sds3 mutations allow CTS1 expression in the absence of Ace2,
CTS1 expression is largely lost in the ace2 swi5 strains,
demonstrating that Swi5 is responsible for CTS1 transcription
in the absence of Ace2.
ChIP experiments were performed to examine binding of
Sin3/Rpd3 complexes to the CTS1 promoter. Sin3, Rpd3, and
Sds3 all bind to CTS1, indicating binding by Rpd3(Large); in
contrast, Rco1, the Rpd3(Small)-specific subunit, does not
bind (Figure 3D). We next compared binding of Rpd3(Large)
to the wild-type CTS1 promoter and the CTS1(nreD) promoter
deletion. Deleting the NRE element results in a substantial
reduction of binding of Sin3 (Figure 3E) and Sds3 (Figure 3F),
demonstrating that the NRE is required for recruiting Rpd3
(Large) to CTS1. As a control, we measured binding to the
INO1 promoter, known to bind Sin3/Rpd3 (Kadosh and
Struhl, 1997). Binding to INO1 was unaffected in the
CTS1(nreD) strain, demonstrating specificity. Interestingly,
Rpd3(Large) binds to the CLB2 promoter as well, which is
also bound by Fkh1 and Fkh2. An ace2 mutation does not
affect Rpd3(Large) binding to CTS1 (data not shown). We
next examined histone acetylation directly at CTS1 in wild-
type and rpd3 strains. The rpd3 mutation results in decreased
histone H3 at CTS1, and increased levels of acetylated H3 and
acetylated H4 (Figure 4A). Normalizing the acetylated his-
tone ChIP signals to the levels of H3 at the promoter shows
that the rpd3 mutation results in a marked increase in histone
acetylation at the CTS1 promoter (Figure 4B). We also
determined whether Rpd3(Large) binding to promoters was
dependent upon Fkh proteins, measuring Sin3-HA binding in
wild-type, fkh1 and fkh2 single mutants, and in the fkh1 fkh2
double mutant (Figure 4C). The Sin3 ChIP signal at the CLB2
and CTS1 promoters is abolished in the fkh1 fkh2 double
mutant, but largely unaffected in the fkh1 or fkh2 single
mutants. We conclude that either Fkh1 or Fkh2 is competent
to recruit Rpd3(Large) to the CLB2 and CTS1 promoters. In
contrast, Rpd3(L) binding to the INO1 promoter is unaffected
in the fkh1 fkh2 double mutant. In summary, these experi-
ments demonstrate that the Rpd3(Large) HDAC complex is
recruited to the CTS1 promoter by Fkh1 and Fkh2,
Rpd3(Large) and functions to specifically reduce CTS1 activa-
tion by Swi5.
Different in vivo DNA binding by Ace2 and Swi5
Although in vitro binding experiments show that Ace2 and
Swi5 recognize the same sequences in promoters, they can
activate transcription of different genes in vivo (Dohrmann
et al, 1996). Ace2, but not Swi5, activates CTS1 expression,
and Swi5, but not Ace2, activates HO. Ace2 and Swi5 are
cell-cycle-regulated transcription factors, and cells with a
GALHCDC20 allele were synchronized within the cell cycle
by removing galactose to arrest in mitosis, followed by re-
addition of galactose (Bhoite et al, 2001). Flow cytometry and
analysis of cycle-regulated mRNAs show a high degree of
synchrony (Figure 2C and data not shown). ChIP experiments
were performed with synchronized cells showing Swi5-Myc
binding to the HO and CTS1 promoters (Figure 2D). Swi5-Myc
binds to both HO and CTS1, although it does not activate
CTS1. Thus, the NRE in CTS1 does not prevent Swi5 from
binding, but acts to prevent promoter-bound Swi5 from
activating transcription.
ChIP with Ace2-Myc shows binding to CTS1 but not to HO
(Figure 2C); Ace2 does not activate HO although it binds
in vitro (Dohrmann et al, 1996). Swi5 does not block Ace2
from binding to HO, as no binding of Ace2 to HO is seen in
either an SWI5 or an swi5 strain. Thus, there are distinct
mechanisms of promoter restriction for Swi5 and Ace2 at HO
and CTS1. Swi5 binds to CTS1, but does not activate tran-
scription. In contrast, Ace2 is unable to activate HO transcrip-
tion simply because it does not bind to the HO promoter.
During the cell cycle, Swi5 binds DNA before Ace2 (Figure 2C
and D), and Swi5 enters the nucleus before Ace2 (Sbia et al,
2007). Work is in progress to understand why Ace2 is unable
to bind to and activate expression of the HO gene, although
Ace2 binds well to HO in vitro.
Genome-wide analysis of regulation and binding by
Swi5 and Ace2
To determine whether these distinct promoter restriction
mechanisms are general for all Ace2 and/or Swi5 targets
throughout the genome, global expression, chromatin bind-
ing, and binding motif correlations were undertaken. First,
genome-wide experiments were performed to determine
whether these Ace2- and Swi5-binding patterns are seen at
other promoters. Expression microarrays were used to define
their targets of regulation and revealed that the RNA levels for
66 genes was reduced more than two-fold in either the ace2
single mutant or the swi5 single mutant or the ace2 swi5
double mutant (Supplementary data). To more stringently
identify genes directly regulated by Ace2 and Swi5, we
eliminated genes that are not cell cycle regulated (Cho et al,
1998; Spellman et al, 1998; Pramila et al, 2006). Among the
23 remaining genes, eight were activated only by Ace2, six by
Swi5 only, and nine required either Ace2 or Swi5 for activa-
tion (Figure 5A). Expression of CDC6 and PCL2 was reduced
less than two-fold, but these genes were included in our
analysis as their expression was previously shown to be
activated by Ace2 or Swi5 (Piatti et al, 1995; Aerne et al,
1998; McBride et al, 1999; Doolin et al, 2001). RT–PCR
experiments confirm the dependence of these genes on
Ace2 and/or Swi5 (Supplementary Figure S1).
To determine Ace2 and Swi5 genomic-binding locations,
Ace2-Myc and Swi5-Myc strains were synchronized at M
with GALHCDC20, and samples taken at timed intervals
after the release were processed for ChIP and hybridized
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to whole-genome DNA microarrays. The complete
experiment was performed three times (Supplementary
data). Some promoters were bound by both Swi5 and
Ace2, and some by Swi5 only; but none of the selected
promoters were bound by Ace2 only (Figure 5D). The
analysis revealed that Ace2 and Swi5 both bind to all
genes activated only by Ace2, but only Swi5 binds to genes
activated only by Swi5. This is the same pattern observed
for CTS1 and HO (Figure 2C and D). Cells synchronized
with GALHCDC20 and ChIPs quantitated with real-time
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PCR confirm the ChIP–chip results for selected representative
genes (Figure 6A).
Upstream Fkh sites define genes that are activated only
by Ace2
At CTS1, Fkh binding is required to prevent Swi5 from
activating transcription. To assess whether Fkh-binding
sites are present at other genes activated by Ace2 but not
by Swi5 (Ace2-only genes), we analyzed data from the
expression microarray and ChIP–chip experiments (Figure
5A and D) in relation to the genome-wide distribution of
DNA sequence motifs bound by Ace2/Swi5 and/or Fkh1/2
(MacIsaac et al, 2006) (Figure 5B). Ace2-only genes contain

























Figure 4 rpd3 affects histone acetylation and fkh mutation affect Rpd3(L) binding to CTS1. (A) Lysates from wild-type or rpd3 mutant cells
were immunoprecipitated with either no antibody, anti-H3, anti-H3(K14-Ac), or anti-H4(-Ac). PCR reactions were performed with CTS1 and
control primers, and the ratio of these ChIP values were normalized to ratios for PCR reactions with the two primer sets using input DNA. Error
bars show the standard deviation of the ChIP PCR reactions performed in triplicate. (B) Using the data in part (A), the ChIP ratios for H3(K14-
Ac) and H4(-Ac) were divided by the ChIP ratios for histone H3. (C) ChIP assays of Sin3-HA binding in wild-type, fkh1, fkh2, and fkh1 fkh2
strains show that either Fkh1 or Fkh2 can recruit Sin3-HA to CLB2 and CTS1, while fkh mutations do not affect Sin3-HA binding to the INO1
promoter.
Figure 3 Rpd3(Large) regulates CTS1 via the NRE. (A) RT–PCR assays show that sin3 and sds3 mutations allow CTS1 expression despite an
ace2 mutation, while rco1 does not suppress. RNA values are normalized to the ace2 mutant (defined as 1); CTS1 RNA in the ace2 mutant is 2%
of the ACE2þ strain. (B) RT–PCR assays show that CTS1 can be activated by Swi5 in an sin3 mutant, and that the effects of an sin3 mutation
and deletion of the NRE promoter element are not additive. RNA values are normalized to the CTS1(WT) ACE2 SWI5 SIN3 strain (defined as
100), and the error bars show the standard deviation of the triplicate PCR reactions. (C) RT–PCR assays show that CTS1 can be activated by
Swi5 in an sds3 mutant, and that the effects of an sds3 mutation and deletion of the NRE promoter element are not additive. RNA values are
normalized to the CTS1(WT) ACE2 SWI5 SIN3 strain (defined as 100), and the error bars show the standard deviation of the triplicate PCR
reactions. (D) The Sin3-HA, Rpd3-Myc, and Sds3-Myc components of Rpd3(Large) bind to CTS1 in a ChIP assay, while the Rco1-Myc
component of Rpd3(Small) does not. Error bars show the standard deviation of the ChIP PCR reactions performed in triplicate. (E) ChIP assay
shows Sin3-HA binding to CTS1, CLB2, and INO1. Deletion of the NRE reduces Sin3 binding. Error bars show the standard deviation of the ChIP
PCR reactions performed in triplicate. (F) ChIP assay shows Sds3-HA binding to CTS1, CLB2, and INO1. Deletion of the NRE reduces Sds3
binding. Error bars show the standard deviation of the ChIP PCR reactions performed in triplicate. (G) ChIP assay shows Sds3-HA binding to
EGT2 and CTS1. Insertion of the NRE element from CTS1 into the EGT2(þNRE) promoter increases Sds3 binding. Error bars show the standard
deviation of the ChIP PCR reactions performed in triplicate.
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contain Ace2/Swi5 sites but lack Fkh sites (yellow)
(Figure 7A). Examining genes whose expression is reduced
in an ace2 mutant, we find that both Ace2 (Figure 7B) and
Swi5 (Figure 7C) bind, and all of these genes contain Fkh-
binding sites. In contrast, Swi5 (Figure 7D) but not Ace2
(Figure 7E) binds to Swi5-only genes, and none of these
contain Fkh sites. The Ace2-only genes all contain multiple
Fkh sites, but there is no common pattern of binding site
spacing or orientation in the three classes of promoters
(Figure 6B). ChIP–chip experiments (Simon et al, 2001)
show Fkh1 and Fkh2 bind to the Ace2-only genes, but not
to either class of gene activated by Swi5 (Figure 5C).
Introduction of Fkh sites into promoters reduces
activation by Swi5 but not Ace2
To test whether Fkh sites are sufficient to reduce activation by
Swi5, we inserted the CTS1 NRE, containing Fkh-binding
sites into the native promoters of the EGT2 and SIC1 genes.
EGT2 and SIC1 are activated by both Ace2 and Swi5 (Knapp
et al, 1996; Kovacech et al, 1996; Toyn et al, 1997), and are
not normally bound by Fkh1 or Fkh2 (Simon et al, 2001).
Expression of EGT2 and SIC1 is modestly reduced in ace2 or
swi5 single mutants, but more substantially reduced in the
ace2 swi5 double mutant (Figure 8). In the ace2 swi5 strain,
EGT2 levels are reduced to undetectable levels, while SIC1
mRNA is reduced to 30% of wild type. Presumably, there are
other basal activators of SIC1 expression in addition to Ace2
and Swi5. In contrast, CTS1 mRNA is absent in the ace2 SWI5
strain.
We made two types of insertions into the EGT2 and SIC1
promoters. Both were made at the endogenous chromosomal
locations with no loss of native sequences. The
EGT2(þNRE) and SIC1(þNRE) promoters have a region
from the CTS1 promoter with the entire NRE element in-
serted, while the EGT2(þNRE-m) and SIC1(þNRE-m) pro-
moters contain a similar sized fragment from CTS1 except for
sequence substitutions throughout the four Fkh sites (see
Figure 1). Expression of EGT2(þNRE) and SIC1(þNRE) is
significantly reduced in the ace2 strain, where Swi5 is
the remaining major activator (Figure 8). Expression of
SIC1(þNRE) is reduced to nearly the level seen in the ace2
swi5 strain, providing additional evidence that the NRE
blocks activation by Swi5 (Figure 8).
Data from EGT2(þNRE) suggests that the NRE is only
partially able to block Swi5 activation at EGT2. This may be
due to the number and dispersed locations of Swi5/Ace2-
binding motifs throughout the promoter (see Figure 6B). For
both promoters, however, the NRE reproducibly confers at
least a two-fold reduction only in Swi5-dependent activation,
with no effect on Ace2-dependent activation (Figure 8). This
results in an approximately three-fold bias for Ace2 relative to
Swi5 for these promoters, which are normally equivalently
sensitive to either activator. The EGT2(þNRE-m) and
SIC1(þNRE-m) promoters with a CTS1 promoter fragment
lacking the Fkh sites are expressed at levels similar to that of
wild-type promoters, indicating that the observed effects are
not due to alterations in spacing or architecture within these
promoters. These experiments show that Fkh sites are suffi-
cient to prevent Swi5 from activating specific target genes.
We also examined Sds3 binding to the EGT2(þNRE)
promoter. As shown in Figure 3G, there is increased Sds3
binding to EGT2(þNRE) compared to wild-type EGT2. This
Figure 5 Expression and promoter occupancy of Ace2- and Swi5-dependent genes. (A) Relative RNA levels in ace2, swi5, and ace2 swi5 strains
as a log2 ratio (mutant/WT). RNA levels with greater than a two-fold reduction are shown in red. (B) The presence of binding sites for Ace2/
Swi5 or Fkh1/2 in promoters, from MacIsaac et al (2006). (C) The degree of Fkh1 or Fkh2 binding by ChIP–chip are the binding ratios from the
data supporting Simon et al (2001), with binding levels greater than two standard deviations from the mean shown in red. (D) Ace2 and Swi5
binding as a heat map showing the results for an untagged control strain, and for the Ace2-Myc and Swi5-Myc strains at the CDC20 arrest (t¼ 0)
and time points after release. The heatmap represents the results of 33 microarray experiments (Materials and methods) with the number of
repeats for each time point as shown in Supplementary Table 3. Percentile ranks were calculated for each experiment and then averaged for
each time point to generate the values shown. A color scale represents the degree of binding expressed as percentile ranks of ChIP enrichment.
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demonstrates that the NRE element with Fkh-binding sites is
sufficient to recruit the Rpd3(Large) complex to promoters.
DNA binding by Fkh1 and Fkh2 varies during the cell
cycle but this is unlikely to be required for the
antiactivation specificity
Fkh1 and Fkh2 binding at CLB2 group promoters activates
transcription in G2, yet binding at Ace2-activated targets
results in selective repression in G2/M. Additionally, binding
of Swi5 and Ace2 to their G1 targets occurs at different times,
with Swi5 preceding Ace2. Thus, we hypothesized that
differences in Fkh1 and Fkh2 occupancy at CTS1 and CLB2
with respect to the cell cycle might determine their roles as
either activators versus selective antiactivators. We therefore
directly analyzed the Fkh1 and Fkh2 proteins during the
cell cycle by ChIP and by western immunoblotting
(Supplementary Figure S2). During the cell cycle, ChIP
experiments show significant variation in binding to CTS1
and CLB2 over time, with maxima during the M and early G1
period. Additionally, western blots show subtle differences in
abundance and mobility of Fkh proteins during the cell cycle.
However, the cell cycle times of these changes do not explain
why Fkh1 and Fkh2 differently repress and activate CTS1 and
CLB2. Thus, it appears unlikely that the mechanism of Swi5-
specific antiactivation involves restricting Fkh occupancy of
CTS1 to a limited period of the cell cycle.
Activation of CLB2 involves Fkh2 recruiting the Ndd1
activator at certain cell cycle times (Koranda et al, 2000). At
other times of the cell cycle, Fkh1 and Fkh2, in the absence of
Ndd1, actually repress CLB2 transcription (Hollenhorst et al,
2000), an idea supported by the observation that fkh1 muta-
tions suppress the lethality caused by deletion of the NDD1
gene (Koranda et al, 2000). CLB2 activation during G2
requires the presence of Mcm1 at the promoter (Althoefer
et al, 1995a). At CTS1, in the absence of Mcm1 interaction,
but where there are multiple Fkh-binding sites, Fkh1 and
Fkh2 binding may continuously reinforce each other, result-
ing in a sharp peak of Fkh2 binding to CTS1 at G2/M and a
subsequent Fkh1 peak in M/G1, resulting in sufficient occu-
pancy by both factors for full repression. Thus, promoter
context and neighboring DNA-binding proteins may deter-
mine the activity of Fkh1 and Fkh2.
Fkh proteins do not bind to the CLB2 ORF
Because both Ace2 and Swi5 are equivalently able to program
Pol II transcription in Fkh-independent contexts, we hypothe-
sized that the mechanism of discrimination may involve FKH-
dependent differences in the ability of Ace2 and Swi5 to
program a step subsequent to Pol II recruitment. Morillon
et al (2003) reported that Fkh1, in addition to binding to the
CLB2 promoter, also binds to the CLB2-coding region. The
authors postulated that Fkh proteins influence transcriptional
elongation and termination, and regulate phosphorylation of
the Pol II CTD. CLB2 is cell cycle regulated, expressed soon
after the release during G2. One prediction based on Morillon
et al (2003) is that the Fkh proteins would be bound to the
promoter before expression, and then appear to travel down
the ORF after transcription begins. A variation would be for
Fkh1 to be bound to the CLB2 ORF throughout the cell cycle,
irrespective of whether the gene is transcribed or not.
To test these models, we examined the kinetics of Fkh1
binding to this ORF, using chromatin extracts from synchro-
nized cells expressing Fkh1-HA. However, our ChIP assays
provided no evidence for Fkh1 binding to the CLB2 ORF at a
level above background during the cell cycle (Supplementary
Figure S3A). We also looked for Fkh1 binding to the CLB2
ORF in log phase cells, as nonsynchronized cells had been
used by Morillon et al (2003). Once again, we did not see any
Fkh1 binding to the CLB2 ORF, although we did see strong
binding to the CLB2 promoter (Figure 2E) in both sets of
samples, as well as strongly periodic binding to the CTS1
promoter.
Based on the suggestion that Fkh proteins regulate pol II
CTD phosphorylation (Morillon et al, 2003), we considered a
model where Swi5 binding leads to pol II recruitment to
CTS1, but the Fkh proteins prevent pol II from initiating
transcription. However, ChIP shows equivalent pol II binding
to CTS1 in WT versus swi5 strains, and pol II binding is
reduced to equivalent levels in ace2 and ace2 swi5 strains
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Figure 6 Binding of Swi5 and Ace2 to target genes. (A) Ace2-Myc
and Swi5-Myc binding in synchronized GAL-CDC20 cells were
measured by real-time PCR after ChIP. ChIP-binding ratios are
expressed as a ratio to an internal control. (B) Diagrams show the
positions of Ace2- or Swi5-binding sites (yellow arrows) or Fkh-
binding sites (blue arrows) on genes characterized as (1) activated
by Ace2 only, (2) activated by either Ace2 or Swi5, or (3) activated
either by Swi5 only.
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where Swi5 recruits pol II to CTS1, but the Fkh proteins block
the pol II from initiating transcription. Thus, the selective
antiactivation mechanism impinges on the transcriptional
activation program at an earlier step.
Conclusions
We have analyzed divergent regulation by paralogous tran-
scription factors with identical DNA-binding domains. Ace2 is
prevented from binding to genes activated solely by Swi5. In
contrast, Swi5 binds to, but cannot activate, genes like CTS1
due to the presence of Fkh1 and Fkh2, which function as
selective antiactivators. Antiactivation has been observed in
eukaryotes before at the yeast GAL genes (Traven et al, 2006).
Here, the Gal80 protein blocks the activation potential of the
Gal4 activator, and antiactivation requires physical inter-
action between the two proteins. In the presence of galactose,
the Gal3 protein overcomes the antiactivation. In contrast,
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Figure 7 Genome-wide analysis of expression, binding sites, and factor binding. Promoters with Ace2/Swi5-binding sites and Fkh-binding
sites are red, those with Ace2/Swi5 but no Fkh sites are yellow, those with only Fkh sites are blue, and those with neither site are gray.
(A) log2(ace2/WT) plotted versus log2(swi5/WT) microarray data, showing Ace2-only genes do contain Fkh sites and Swi5-only genes do not.
(B) log2(ace2/WT) microarray data plotted versus Ace2 ChIP–chip occupancy data, showing Ace2 binding to Ace2-only genes. (C) log2(ace2/
WT) microarray data plotted versus Swi5 ChIP–chip occupancy data, showing Swi5 binding to Ace2-only genes. (D) log2(swi5/WT) microarray
data plotted versus Swi5 ChIP–chip occupancy data, showing Swi5 binding to Swi5-only genes. (E) log2(swi5/WT) microarray data plotted
versus Ace2 ChIP–chip occupancy data, showing Ace2 does not bind to Swi5-only genes.
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separate DNA-binding proteins that bind to separate elements
on the same promoter and the recruitment of a HDAC.
Further work is needed to understand how the Fkh proteins
act as selective antiactivators, blocking activation by Swi5 but
not by Ace2, and the unique attributes possessed by Ace2 that
allow it to overcome this antiactivation.
The Fkh1 and Fkh2 proteins have been previously char-
acterized as activators of the G2/M CLB2 group of genes,
although they may have negative roles at these genes in other
cell cycle phases (Hollenhorst et al, 2000; Kumar et al, 2000;
Zhu et al, 2000). The CLB2 group promoters all contain a
single Mcm1-binding site in close apposition to a single Fkh
consensus site (Althoefer et al, 1995b; Pic et al, 2000; Boros
et al, 2003). Here, we show that the Ace2-activated/Fkh-anti-
activated group of M/G1 promoters contains multiple Fkh
consensus sites, with no discernible Mcm1-binding se-
quences; additionally, no Mcm1 binding has been detected
at these promoters (data not shown, Simon et al, 2001).
Moreover, Mcm1-Fkh recruit the cell-cycle-regulated tran-
scriptional activator Ndd1 to CLB2-group promoters
(Koranda et al, 2000), but no Ndd1 recruitment to Ace2-
regulated promoters has been detected (Simon et al, 2001).
These differences may explain in part the contrasting earlier
function of Fkh proteins at G2/M versus the Ace2 and Swi5-
bound genes expressed in late M and G1 phases. We propose
that Ace2-activated M/G1 target genes are selectively regu-
lated through a novel antiactivation mechanism, in part
comprising HDAC recruitment by the Fkh1/Fkh2 paralogs,
determining which target genes are activated by Ace2 as
opposed to Swi5 during the ordered cascade of the cell cycle
transcriptional program (Simon et al, 2001; Pramila et al,
2006). It is possible that the acetylation of Swi5 is important
for its function as an activator, and the HDACs block this
activation; further work will be needed to test this hypothesis.
Materials and methods
All yeast strains used are listed in Supplementary Table 1 and are
isogenic in the W303 background (Thomas and Rothstein, 1989).
Standard genetic methods were used for strain construction
(Rothstein, 1991; Sherman, 1991), and details on construction of
specific alleles are presented in the Supplementary data. Cells were
grown at 301C in YEPD medium (Sherman, 1991). Cell cycle
synchronization was performed either by a-factor arrest and release
as described (Mitra et al, 2006), or by galactose withdrawal and
re-addition with a GALHCDC20 strain (Bhoite et al, 2001). A high
degree of synchrony was demonstrated by flow cytometry analysis,
budding indices, and analysis of cycle-regulated mRNAs (data not
shown).
RNA levels were determined with S1 nuclease protection assays
as described (Voth et al, 2005) or by RT–PCR. For RT–PCR, DNA-
free total RNA was purified from mid-log cultures by hot-acid
phenol extraction followed by precipitation through CsCl by
ultracentrifugation (Ausubel et al, 1987). Gene expression levels
were quantitated by randomly primed cDNA synthesis with M-MLV
Reverse Transcriptase (Invitrogen), followed by real-time quantita-
tive PCR. For microarrays, RNA from ace2, swi5, and ace2 swi5
strains were reverse transcribed and each was competitively
hybridized with RNA from wild-type strains on Agilent oligonucleo-
tide arrays. Swi5 levels in immunoblots were quantitated using an
Odyssey system (Li-Cor).
All ChIPs (except for ChIP–chips) were performed as described
(Bhoite et al, 2001) using 9E11 (Abcam) or 4A6 (Upstate)
monoclonal antibody to the Myc epitope, and 12CA5 antibody to
the HA epitope (University of Utah Bioprocessing Resource), anti-
histone H3 (07–690, Upstate), anti-histone H3(Ac-Lys14) (07–353,
Upstate), anti-acetyl-histone H4 (06–598, Upstate), and antibody
coated magnetic beads (Rabbit and Pan Mouse IgG beads, Dynal
Biotech). ChIP assays were analyzed as described, either using
multiplex PCR (Bhoite et al, 2001) or by real-time PCR (Eriksson
et al, 2004). Oligonucleotides used for ChIP, RT–PCR, or S1 nuclease
protection are listed in Supplementary Table 2. Immunoblots of
proteins transferred from low-bis-polyacrylamide gel electrophor-
esis (Whalen and Steward, 1993) were probed with anti-HA, anti-
Myc, and anti-PGK 22C5-D8 (Molecular Probes) antibodies, and
visualized with an Odyssey Infrared system (LI-COR Biosciences
Lincoln, NE). Quantitation of ChIP was calculated as described
(Eriksson et al, 2004), except that ChIP signals were additionally
normalized to the total DNA amount from input chromatin for
each sample. Standard deviations for normalized PCR replicates
were calculated using Equation (7) of van Kempen and van Vliet
(2000).
For the ChIP–chip experiments, eight separate synchrony and
immunoprecipitation experiments were performed (four for Ace2
and four for Swi5). A total of 33 ChIP–chip hybridizations were
performed, and are listed in Supplementary Table 3. The ChIP–chip
experiments were performed as essentially as described (Lieb et al,
2001), with complete details provided in the Supplementary data.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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Figure 8 The NRE element reduces activation by Swi5. RT–PCR assays show CTS1 is only activated by Ace2, while EGT2 and SIC1 is activated
by either Ace2 or Swi5. Insertion of the CTS1 NRE into EGT2 and SIC1 (EGT2(þNRE) and SIC1(þNRE)) reduces SWI5-dependent activation,
while insertion of a CTS1 NRE fragment with sequence substitutions through the four four Fkh sites (EGT2(þNRE-m) and SIC1(þNRE-m))
has no effect on SWI5-dependent activation. The RNA values for each set of strains are normalized to the ACE2 SWI5 strain (defined as 100),
and the error bars show the standard deviation of the triplicate PCR reactions.
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